The Washington Times | 'Cutting-edge science': OCD drug designed by artificial intelligence

Updated: Apr 17


Two pharmaceutical companies have embarked on a brave new world, having begun human testing for the first time on a drug treatment for obsessive-compulsive disorder designed by artificial intelligence.


“Different properties of molecules will create different side effects, and so it’s a very intriguing idea to use AI, a computer, to help predict,” said Dr. Wendell Gibby, a radiologist in Utah and CEO of Novarad, a health care technology and imaging company. “AI is a very powerful technique that’s being used across many fields of medicine, especially in radiology.”


Read the full article in The Washington Times.



Novarad Health Care Technology Innovation
Novarad HEI Logo 2017 Red Swirl Black Te

CORPORATE HEADQUARTERS

752 East 1180 South, Suite 200

American Fork, Utah  84003

(877) 668-2723 phone

UNITED KINGDOM

12 Kingsbury Trading Estate Church Lane

Kingsbury London United Kingdom

NW9 8AU

+44 (0) 208 205 9500 phone

+44 (0) 208 205 0585 fax

LATIN AMERICA

2 Calle A 6-28 zona 10 Edificio Verona, Oficina 502
Edificio Verona, Oficina 502
Guatemala, Guatemala

ASIA - PACIFIC

407 Prestige Tower F. Ortiga Jr. Road
Ortigas Center, Pasig City Philippines, 1605
Phone: +632.661.6161
Fax: +632.661.4334

© 2020 Novarad®